2025 Q3 -tulosraportti
Vain PDF
43 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
3 563
Myynti
Määrä
3 506
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 360 | - | - | ||
| 120 | - | - | ||
| 50 | - | - | ||
| 76 | - | - | ||
| 647 | - | - |
Ylin
6,95VWAP
Alin
6,845VaihtoMäärä
0,9 135 337
VWAP
Ylin
6,95Alin
6,845VaihtoMäärä
0,9 135 337
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 151 821 | 151 821 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 151 821 | 151 821 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11.2025 | |
| 2025 Q2 -tulosraportti | 27.8.2025 | |
| 2025 Q1 -tulosraportti | 22.5.2025 | |
| 2024 Q4 -tulosraportti | 25.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
1 päivä sitten1 päivä sittenClinical progress and milestones in H1 2026 Across Cereno Scientific’s portfolio, we continue to advance programs targeting root disease mechanisms: 🔹 CS1, our lead HDAC inhibitor in PAH, is progressing toward a global Phase IIb trial, building on encouraging Phase IIa data, FDA Fast Track designation and Orphan Drug Designation (ODD). First patient is anticipated to enter the trial in Q2 2026. 🔹 CS014, our second HDAC inhibitor, is advancing toward Phase II development, supported by strong non-clinical and Phase I data demonstrating favorable safety, tolerability, and exposure levels relevant to fibrosis and vascular remodeling. 🔹 We are pursuing participation in international scientific conferences, alongside publications in progress, as we continue contributing to and shaping the scientific dialogue around the pioneering approach of epigenetic modulation through HDAC inhibition in cardiovascular and pulmonary disease. 🔹 We are continuing targeted business development activities supporting collaborations and partnering.
5.1.5.1.Oh well, time to strap in for a quiet year ’26. Not much expected outside of new trials starting (which in and of itself is of course good, but will likely have no effect on stock price).
·20 t sittenO grazie mama mia…Are you kidding? ”A calm year. Nothing is happening.”??? We have within a month the biggest triggers in the company's history…
·30.12.2025I have previously owned Cerenoed with an okay profit. The study is, however, well underway. Perhaps the Prolight Diagnostics stock is a better candidate to detect and prevent poor heart and circulatory conditions?
·20.12.2025I've been thinking a bit about Merck's acquisition of Sotatercept. Or that they acquired all of Acceleron Pharma. In 2021. Sotatercept was in phase 3 then. A huge sum, but Merck went all in with a bid. Only now after 10 years in Cereno do I think about this. Yes, it can be a good acquisition sum, but we still have 2-3 years before we approach phase 3 studies. I find it strange again that anyone at all thinks a deal can come at any time 🤔 I'm holding mine. But also interesting to see how the Acceleron share developed towards the acquisition 🤔 there was no 10x increase..·23.12.2025Hi Sjabby…. Nice to see that you are more positive about Cereno's future. I actually think you always were, but wanted in cheaper 😉 Anyway regarding the deal… By deal is not meant only a pure exit but also partnership. Now the cash is replenished, but that doesn't stop any potential partner from coming in. Then there are countless possible scenarios for what the partnership could look like. Regardless, we are heading towards a fantastic year 2026 where knowledge and patience will pay off. Good luck, guys and girls 😉- 11.12.202511.12.2025The P2B study for CS1 will have topline readouts ready sometime in Q4 of 2028. If we take the assumption (to clarify, I have not checked statistics on this) that most BP buyouts of a drug are done post p2 and pre p3 that would mean we’re still years from an exit. Patient mans game, I suppose. But there’s also plenty of good in the situation. Cereno resolved their finances with much better conditions than what I could have ever predicted, so Kudos to them. As long as cashburn doesn’t significantly increase the finances are well supported for a good while. I also eagerly await the new data for CS014 they’re about to release. Hopefully it will support the stock price to stabilize.
·12.12.2025Are there examples of bidding wars between BP recently, the bids often come from zero holdings or smaller stakes? 🤔
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
43 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten1 päivä sittenClinical progress and milestones in H1 2026 Across Cereno Scientific’s portfolio, we continue to advance programs targeting root disease mechanisms: 🔹 CS1, our lead HDAC inhibitor in PAH, is progressing toward a global Phase IIb trial, building on encouraging Phase IIa data, FDA Fast Track designation and Orphan Drug Designation (ODD). First patient is anticipated to enter the trial in Q2 2026. 🔹 CS014, our second HDAC inhibitor, is advancing toward Phase II development, supported by strong non-clinical and Phase I data demonstrating favorable safety, tolerability, and exposure levels relevant to fibrosis and vascular remodeling. 🔹 We are pursuing participation in international scientific conferences, alongside publications in progress, as we continue contributing to and shaping the scientific dialogue around the pioneering approach of epigenetic modulation through HDAC inhibition in cardiovascular and pulmonary disease. 🔹 We are continuing targeted business development activities supporting collaborations and partnering.
- 5.1.5.1.Oh well, time to strap in for a quiet year ’26. Not much expected outside of new trials starting (which in and of itself is of course good, but will likely have no effect on stock price).·20 t sittenO grazie mama mia…Are you kidding? ”A calm year. Nothing is happening.”??? We have within a month the biggest triggers in the company's history…
- ·30.12.2025I have previously owned Cerenoed with an okay profit. The study is, however, well underway. Perhaps the Prolight Diagnostics stock is a better candidate to detect and prevent poor heart and circulatory conditions?
- ·20.12.2025I've been thinking a bit about Merck's acquisition of Sotatercept. Or that they acquired all of Acceleron Pharma. In 2021. Sotatercept was in phase 3 then. A huge sum, but Merck went all in with a bid. Only now after 10 years in Cereno do I think about this. Yes, it can be a good acquisition sum, but we still have 2-3 years before we approach phase 3 studies. I find it strange again that anyone at all thinks a deal can come at any time 🤔 I'm holding mine. But also interesting to see how the Acceleron share developed towards the acquisition 🤔 there was no 10x increase..·23.12.2025Hi Sjabby…. Nice to see that you are more positive about Cereno's future. I actually think you always were, but wanted in cheaper 😉 Anyway regarding the deal… By deal is not meant only a pure exit but also partnership. Now the cash is replenished, but that doesn't stop any potential partner from coming in. Then there are countless possible scenarios for what the partnership could look like. Regardless, we are heading towards a fantastic year 2026 where knowledge and patience will pay off. Good luck, guys and girls 😉
- 11.12.202511.12.2025The P2B study for CS1 will have topline readouts ready sometime in Q4 of 2028. If we take the assumption (to clarify, I have not checked statistics on this) that most BP buyouts of a drug are done post p2 and pre p3 that would mean we’re still years from an exit. Patient mans game, I suppose. But there’s also plenty of good in the situation. Cereno resolved their finances with much better conditions than what I could have ever predicted, so Kudos to them. As long as cashburn doesn’t significantly increase the finances are well supported for a good while. I also eagerly await the new data for CS014 they’re about to release. Hopefully it will support the stock price to stabilize.·12.12.2025Are there examples of bidding wars between BP recently, the bids often come from zero holdings or smaller stakes? 🤔
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
3 563
Myynti
Määrä
3 506
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 360 | - | - | ||
| 120 | - | - | ||
| 50 | - | - | ||
| 76 | - | - | ||
| 647 | - | - |
Ylin
6,95VWAP
Alin
6,845VaihtoMäärä
0,9 135 337
VWAP
Ylin
6,95Alin
6,845VaihtoMäärä
0,9 135 337
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 151 821 | 151 821 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 151 821 | 151 821 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11.2025 | |
| 2025 Q2 -tulosraportti | 27.8.2025 | |
| 2025 Q1 -tulosraportti | 22.5.2025 | |
| 2024 Q4 -tulosraportti | 25.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
Vain PDF
43 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11.2025 | |
| 2025 Q2 -tulosraportti | 27.8.2025 | |
| 2025 Q1 -tulosraportti | 22.5.2025 | |
| 2024 Q4 -tulosraportti | 25.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten1 päivä sittenClinical progress and milestones in H1 2026 Across Cereno Scientific’s portfolio, we continue to advance programs targeting root disease mechanisms: 🔹 CS1, our lead HDAC inhibitor in PAH, is progressing toward a global Phase IIb trial, building on encouraging Phase IIa data, FDA Fast Track designation and Orphan Drug Designation (ODD). First patient is anticipated to enter the trial in Q2 2026. 🔹 CS014, our second HDAC inhibitor, is advancing toward Phase II development, supported by strong non-clinical and Phase I data demonstrating favorable safety, tolerability, and exposure levels relevant to fibrosis and vascular remodeling. 🔹 We are pursuing participation in international scientific conferences, alongside publications in progress, as we continue contributing to and shaping the scientific dialogue around the pioneering approach of epigenetic modulation through HDAC inhibition in cardiovascular and pulmonary disease. 🔹 We are continuing targeted business development activities supporting collaborations and partnering.
- 5.1.5.1.Oh well, time to strap in for a quiet year ’26. Not much expected outside of new trials starting (which in and of itself is of course good, but will likely have no effect on stock price).·20 t sittenO grazie mama mia…Are you kidding? ”A calm year. Nothing is happening.”??? We have within a month the biggest triggers in the company's history…
- ·30.12.2025I have previously owned Cerenoed with an okay profit. The study is, however, well underway. Perhaps the Prolight Diagnostics stock is a better candidate to detect and prevent poor heart and circulatory conditions?
- ·20.12.2025I've been thinking a bit about Merck's acquisition of Sotatercept. Or that they acquired all of Acceleron Pharma. In 2021. Sotatercept was in phase 3 then. A huge sum, but Merck went all in with a bid. Only now after 10 years in Cereno do I think about this. Yes, it can be a good acquisition sum, but we still have 2-3 years before we approach phase 3 studies. I find it strange again that anyone at all thinks a deal can come at any time 🤔 I'm holding mine. But also interesting to see how the Acceleron share developed towards the acquisition 🤔 there was no 10x increase..·23.12.2025Hi Sjabby…. Nice to see that you are more positive about Cereno's future. I actually think you always were, but wanted in cheaper 😉 Anyway regarding the deal… By deal is not meant only a pure exit but also partnership. Now the cash is replenished, but that doesn't stop any potential partner from coming in. Then there are countless possible scenarios for what the partnership could look like. Regardless, we are heading towards a fantastic year 2026 where knowledge and patience will pay off. Good luck, guys and girls 😉
- 11.12.202511.12.2025The P2B study for CS1 will have topline readouts ready sometime in Q4 of 2028. If we take the assumption (to clarify, I have not checked statistics on this) that most BP buyouts of a drug are done post p2 and pre p3 that would mean we’re still years from an exit. Patient mans game, I suppose. But there’s also plenty of good in the situation. Cereno resolved their finances with much better conditions than what I could have ever predicted, so Kudos to them. As long as cashburn doesn’t significantly increase the finances are well supported for a good while. I also eagerly await the new data for CS014 they’re about to release. Hopefully it will support the stock price to stabilize.·12.12.2025Are there examples of bidding wars between BP recently, the bids often come from zero holdings or smaller stakes? 🤔
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
3 563
Myynti
Määrä
3 506
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 360 | - | - | ||
| 120 | - | - | ||
| 50 | - | - | ||
| 76 | - | - | ||
| 647 | - | - |
Ylin
6,95VWAP
Alin
6,845VaihtoMäärä
0,9 135 337
VWAP
Ylin
6,95Alin
6,845VaihtoMäärä
0,9 135 337
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 151 821 | 151 821 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 151 821 | 151 821 | 0 | 0 |